groups
Navigation Links
groups at medicine technology
Tight Glycemic Control in the ICU
...and decreasing workload in the ICU. Many research groups have been working on their development. There is an approved device for detecting glycemic excursions in outpatients with diabetes that has shown promise in monitoring critically ill patients. The Continuous Glucose Monitoring System (CGMS, Medtron...Optimizing Quality Control Data Management
...tically to other laboratories in defined consensus groups running the same or similar tests. In this manner...can compare its performance to available consensus groups to determine if its performance is as good as those using the same method. If not, the laboratory kn......VTE andall-cause mortality in both dabigatran dose groups were within thepre-specified non- inferiority marg... VTEoccurred at similar rates across all treatment groups (3.0% and3.4% for 150 mg and 220 mg dabigatran etexilate respectively,versus 2.2% enoxaparin). Altho...... for the one to six year oldand 10 to 65 years old groups respectively. Subsequent comparisonwith bleed frequency for each group found that in the one to sixyears of age group the time below 1 IU/dL while on prophylaxis wasassociated with increased incidence of traumatic and spontaneoustotal bleeds (p<0......enefit from the Avandiaswitches implemented by all groups of physicians treating type 2patients. "While the news of Avandia's cardiovascular risk may provide abarrier for some physicians to any oral medications, on the otherhand it could also expedite patients to insulin," said Napolitano."About 30 percent......and 20%. No major bleedswere seen in the PRT054021 groups (0 out of 171, 0%), compared with1 major bleed in the enoxaparin group (1 out of 43, 2.3%). Nosignificant non-major bleeds were identified in the low dose groupof PRT054021 (0 out of 87, 0%) and two in the high dose group ofPRT054021 (2 out of 84, 2.......of theworld's leading research-oriented healthcare groups with corebusinesses in pharmaceuticals and diagnostics. For more than 100years in the U.S., Roche has been committed to developinginnovative products and services that address prevention, diagnosisand treatment of diseases, thus enhancing people's he...... both the placebo-treated and CYT003-QbG10-treated groups asimilar reduction of the EASI scores was measured...udyparticipants were randomized into two treatment groups with 18patients each and received 6 weekly subcutaneous injections ofeither 300 ?g CYT003-QbG10 or p...Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
...ieved by reaching85 percent of the most vulnerable groups -- children under fiveyears of age and pregnant women -- with proven and effectiveprevention and treatment control measures. PMI uses a comprehensiveapproach to prevent and treat malaria supporting four key areas;indoor spraying of homes with insecti......twork of nearly 300 chapters, branches and support groups operateprograms of research, education, support and advocacy. CONTACT: Duane Peters of Lupus Foundation of America,Inc.,+1-202-349-1145 Web site: <a target="_blank" href="http://www.lupus.org//">http://www.lupus.org// Terms and condition...... of the world'sleading research-focused healthcare groups in the fields ofpharmaceuticals and diagnostics. As a supplier of innovativeproducts and services for the early detection, prevention,diagnosis and treatment of disease, the Group contributes on abroad range of fronts to improving people's health and...Genetics Journal Thimerosal/Autism Study the 'Best Science Drug Company Money Can Buy'
...hatbetween the 2005 and 2007 versions, the control groups changed andmajor portions of the original autism sample were removed.Calculations based on the original data indicate that children withautism "were 71% more likely to have been exposed to RhIg in uterothan their non-ASD siblings," according to the S......nce-daily dosingthroughout the 6-month trial. Both groups had a significant improvement in glycemic control, withno increases in hypoglycemia (major hypoglycemic events were .02event/patient/month for both groups) and minimal weight change (.2kg for 303 Algorithm group and -.3 kg for Standard-of-Caregroup).......irelesspreparation by the research and development groups at Sangamo." Clinical Results Presented at ADA Co...he trial.Subjects will be randomized to one of two groups in a 2:1 ratio.The larger group (approximately 66 subjects) will be treated byintramuscular injectio......riences weresimilar in the JANUVIA and non-exposed groups for up to two years(Poster #534-P) The safety and tolerability of JANUVIA was assessed by poolingdata from nine completed Phase IIB and III studies, including thestudies discussed above, ranging from 24 to 104 weeks in duration,and including 5,141 p......ce- daily dosingthroughout the 6-month trial. Both groups had a significantimprovement in glycemic control, with no increases in hypoglycemia(major hypoglycemic events were .02 event/patient/month for bothgroups) and minimal weight change (.2 kg for 303 Algorithm groupand -.3 kg for Standard-of-Care group)....CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
.... Forty healthyvolunteers were divided evenly into groups of 10 subjects. In eachgroup three subjects received a placebo capsule without drug andseven received arimoclomol at either 100 mg (the highest doseprovided in the Phase IIa double-blind and open-label extensionstudies), 200 mg, 400 mg, or 600 mg thr...Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
... event rate in theliraglutide and insulin glargine groups was not significantlydifferent. Mads Krogsgaard Thomsen, executive vice president and chief scienceofficer of Novo Nordisk, said: "We are very pleased with thesefirst results from the liraglutide phase 3 programme, showing thatliraglutide provides ......o ensure blood pressure control inthe two patient groups other non- ARB treatments(hydrochlorothiazide or calcium channel blocker) were added,if needed. After one year's treatment, telmisartan was significantly moreeffective than losartan in reducing the amount of proteinexcreted in the urine. The...Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
...ded. Patients in eachof the three active treatment groups had significantly better (pless than .01 or less) ... active drug were similar acrossmorphine treatment groups regardless of route of administration andconsistent with morphine's known pharmacologic effects (diz...Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
...gnificant reductions inserum phosphorus, with both groups reaching target levels forphosphorus control outlined in the K/DOQI treatment guidelines.Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower thanthose in the Renvela arm (5.3 mg/dL), and this trial did notachieve its primary endpoint of demon...Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
...gnificant reductions inserum phosphorus, with both groups reaching target levels forphosphorus control outlined in the K/DOQI treatment guidelines.Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower thanthose in the Renvela arm (5.3 mg/dL), and this trial did notachieve its primary endpoint of demon......ing anestimated difference of 5.0 mmHg between the groups (p<0.001).Mean ambulatory diastolic blood pres...ty.The most common adverse event in both treatment groups was upperabdominal pain, which occurred in less than 2% of patients. Prexige has a different chemic......hestudy were randomized into one of four treatment groups (300 mg,700 mg or 1000 mg ofatumumab or placebo) and assessed based ontheir of Rheumatology (ACR) and EULAR responses at 24 weeks.Continuation of current stable doses of methotrexate and low dosecorticosteroids were permitted. In the intention-to-......ty.The most common adverse event in both treatment groups was upperabdominal pain, which occurred in less than 2% of patients. Lumiracoxib has a different chemical structure from other COX-2inhibitors. It is the only one that does not contain a sulphurmolecule, which has been associated with sulphur-relate......of theworld's leading research-oriented healthcare groups with corebusinesses in pharmaceuticals and diagnostics. For more than 100years in the U.S., Roche has been committed to developinginnovative products and services that address prevention, diagnosisand treatment of diseases, thus enhancing people's he...Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
...ubjectsin the combined golimumab plus methotrexate groups and 5.9% in theplacebo plus methotrexate group. Through week 52, at least 1serious adverse event was reported for 16.1% of subjects in thecombined golimumab plus methotrexate groups; serious adverse eventswere reported in three subjects after cross ...Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
...lacebo. The p-values for the 75 and 150 mg per day groups comparedto placebo were p=0.2193 and p=0.0557, respectively. For the secondary endpoints of mean IGA score at week 8 and theoverall scaling score at weeks 8 and 12, both liarozole groupsachieved statistically significant differences from placebo (......andomizedtrial evaluated the efficacy of four dose groups of NG2-73 versusplacebo in reducing Latency to Per... to placebo at alldoses. All four NG2-73 treatment groups reported that their sleephad been significantly more refreshing than did the placebo group.At 1, 3, ...Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
...d the secondinjection prior to week 30 in all dose groups and placebo.Following the second injection, subjects are followed for anadditional 30 weeks. "These data are very encouraging and suggest that tgAAC94 hasthe potential to address the unmet medical needs of a significantnumber of inflammatory arthrit......nsityof pain at baseline were 6.3 for the Proellex groups and 6.1 forthe Lucrin group. Statistically signifi...ex groups. Atmonth three all four active treatment groups had statisticallysignificant reduction in pain compared with baseline, with thefollowing scores: 3.7......nd the rate of drug-related rash in both treatment groups waslow: 0.4% for the five-day arm and 2.8% for the seven-day arm. Community-acquired pneumonia is a common and serious illness inthe United States with an estimated four to five million cases peryear, one million of which occur in patients over the ...Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
...d.Subjects were randomized to one of five sequence groups andinstructed to treat four migraine attacks. Patients in four groupsreceived Trexima in three of four attacks and placebo in theremaining attack. Patients in the fifth group received Trexima forall four attacks. In each study, approximately 40 perc......I clinical studies bytargeting higher risk patient groups and surgical procedures wherethe clinical benefits from M6G will be maximised. Neil Clark, Chief Executive of CeNeS, commented: "This furtheranalysis of the recent Phase III trial data supports our statedgoal of delivering M6G to the market as a nov......tion at the higher dose. -- Both active treatment groups had lower pain ratings thanplacebo patients (p les...ce as many patientsin each of the Zenvia treatment groups obtained "a lot" of or"complete" pain relief as that in the placebo group. -- Active treatment with......here was no significant difference between the two groups in the risk of death. - Eprodisate (KIACTA(TM)) did not affect proteinuria, amyloid content in abdominal fat and, as expected, did not change the blood level of serum amyloid A protein. - The frequency and types of adverse events...Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
...treatment-adherent, 71.2% of those in the combined groups receivingAlbuferon every two weeks achieved SVR, versus 53.3% for patientsreceiving Pegasys once a week. The ability to maintain efficacy inheavier patients is of particular importance in certain markets,including the United States, where a large per......aring the averageresponse of the MK-0974 treatment groups (300 mg, 400 mg and 600mg) to the response observed in the placebo group. The study wasnot powered to detect differences between the individual doses ofMK-0974 or between MK-0974 doses and rizatriptan. Study results For the primary endpoint, the ov......ts. In the first stage of the trial, fourtreatment groups received escalating doses of 0.5, 1.5, 5 (mg pertumor), and 15 mg (5 mg in each of 3 tumors). In the ongoing secondstage, patients are treated with the 15 mg dose. The interim study results show that no serious adverse eventsrelated to the study d...Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
...e groupreceiving drug at 4mg/kg/infusion as in the groups receiving 2 or1mg/kg/infusion (42 and 79 days). Mechanism of Action In cell culture and experimental models of disease, SPC2996inhibits the production of the protein Bcl-2 and its beneficialeffects in patients are thought to be due to the drug redu...... populations were matched to ensure that thecohort groups were similar in terms of their baseline risk factorsfor cardiovascular disease. Patients were followed for an averageof slightly over a year. The results demonstrate that: • there was no difference in the overallincidence of heart attack a...... ofthe world's leading research-focused healthcare groups in thefields of pharmaceuticals and diagnostics. As the world's biggestbiotech company and an innovator of products and services for theearly detection, prevention, diagnosis and treatment of diseases,the Group contributes on a broad range of fronts ...Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
... Y-90 dose escalating inincrements of 5mCi/m(2) in groups of 3-6 patients. CT basedmeasurements were used to evaluate tumor response 4, 8, and12-weeks after therapy. Results from the Goshen study site were reported at the meeting.Eleven patients, of whom 9 had previously received systemic therapypredomin......t difference between the Avandia and control groups in the key outcomes of hospitalization or death du... events. -- There was no difference between the groups in mortality, whether cardiovascular deaths or deaths from all causes. -- The interim data ......as we observedthat 100 percent of women in all age groups showed a persistentantibody response to our vaccine," said Barbara Howe, MD, VicePresident and Director, North American Vaccine DevelopmentOrganization, GlaxoSmithKline. "As women age, their immuneresponses typically decline. We designed our cervical......C. The ASCIadministration will be initiated in two groups of patients: aftersurgery and standard chemotherapy in one group of patients andafter surgery in patients who are not receiving chemotherapy. Theprimary endpoint of the trial is disease-free survival. "GSK recognizes the need for further investigati...NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien Tablets
...y of pharmacokineticsbetween oral spray and tablet groups as determined by the maximumdrug concentration (Cmax) and total exposure to drug(area-under-the-curve/AUC(0-inf)). These results will be used tosupport NovaDel's NDA submission this year. In addition, NovaDelalso conducted assessments on the speed of......nths of treatment the values for thefour treatment groups were similar to the values at three months.The tre...from low to normal values in theAndroxal treatment groups were similar to the LH responses. FSHdecreased statistically significantly (p less than 0.0001) in t......r the two routes of administration with both groups of patients achieving an overall response rate (complete and partial response) of 42 percent The trial included 24 patients who were randomized to receiveeither SC or IV injections of VELCADE at the standard dose of 1.3mg/m2 twice weekly for t......ant group). Six weeks after liver surgery, both groups of patients receivedan initial dose of 40 - 50 mCi/m2 of 131I-labetuzumab, followed bya second infusion three months later. At the time of reporting,62.5% of patients (10/16) in the adjuvant group remaineddisease-free. For the non-adjuvant group, 25%......ddition, nine-monthstent thrombosis rates for both groups were low and similar for theTAXUS Liberte Stent (0.8 percent) and control stent (0.7 percent,p=1.0). "ATLAS clinical outcomes highlight that despite more complexlesions, the TAXUS Liberte Stent performed extremely well andachieved similar rates of d...Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
...per week were randomized to one of three treatment groups receivingMF101 (5 grams/day), MF101 (10 grams/day), or placebo for twelveweeks. The trial was led by Dr. Deborah Grady at the University ofCalifornia, San Francisco and was conducted at six medical centersin the United States: University of Californi......s no statistical significant differencebetween the groups (81% for SOC; 73% for TNFerade, p=0.5196).Surgical resections occurred in 15% of patients in the TNFerade +SOC group and 11% in the SOC group. The safety analysis indicated that there was no statisticallysignificant difference in the occurrence of s...... ofthe world's leading research-focused healthcare groups in thefields of pharmaceuticals and diagnostics. As the world's biggestbiotech company and an innovator of products and services for theearly detection, prevention, diagnosis and treatment of diseases,the Group contributes on a broad range of fronts ......nd Europe. TIME-2 will compare threedifferent dose groups of tanespimycin each in combination withbortezomib. Eligible patients must have failed three prior multiplemyeloma regimens, including one each of bortezomib and lenalidomide(Revlimid(R)). The primary endpoint is objective response rate. TIME-1 is a...... ofthe world's leading research-focused healthcare groups in thefields of pharmaceuticals and diagnostics. As the world's biggestbiotech company and an innovator of products and services for theearly detection, prevention, diagnosis and treatment of diseases,the Group contributes on a broad range of fronts ...Medicure's MEND-CABG Trial Results Published in Peer Reviewed Journal
... lower incidence of atrialfibrillation in the MC-1 groups (250 mg @.7% and 750 mg @.0%)compared to the placebo group (11.9%) between post operative day(POD) four and the end of the trial. "Atrial fibrillation is one of the most common complicationsafter CABG surgery, and is associated with a significant in...Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
...f lung infection tothe naked eye, while lower-dose groups did show visible infection.This dose-related response was noteworthy given that viral loadswere consistent among the subjects receiving the various dosagesand the control group. Ten days of ongoing Alferon-LDO prophylaxisand treatment reduced the sev...DP-b99 Phase IIb Trial Results to be Presented at the European Stroke Conference
...ically, the recoveryrate in the DP-b99 and placebo groups per modified Rankin scale was30.6% and 16.0% (p=0.05), per NIHSS was 23.6% and 12.0% (p=0.08),and defined by either scale was 37.5% and 18.7% (p=0.02),respectively. The day 90 median change from baseline was 6.0 and5.0 NIHSS points in the DP-b99 and ......nt virus. These patients represent oneof the major groups who could potentially benefit fromnovel-mechanism HIV drugs such as bevirimat." About Panacos Panacos is developing the next generation of anti-infectiveproducts through discovery and development of small molecule oraldrugs for the treatment of HIV...Other ContentsneurobiologicalneurobiologicalneurobiologicalliveliveliveliveliveliveliveliveliveliveatrophyatrophyatrophynewbornnewbornnewbornnewbornnewbornOther TagsPAPPAPPAPPAPPAPPAPChromogenMixerRADISHOther Tagsstruggle 2struggle 3struggle 4struggle 5struggle 6contradictory 2serves 2serves 3serves 4serves 5serves 6serves 7serves 8serves 9
(Date:8/20/2008)...Wireless Data Communications Link School ...L, N.J., Aug. 20 /PRNewswire-FirstCall/ -- BIO-key...leader in finger-based biometric,identification an...d the,availability of MobileSRO(TM) and MobileCamp...ent solutions for K-12 schools and higher,educatio...
(Date:8/20/2008)...2008 New phase 2 data published today in The Lan...4 demonstrates activity in nonsense-mutation cysti...h PTC124 results in statistically significant impr...nts with nonsense-mutation CF. The study was cond...n Jerusalem, Israel and sponsored by PTC Therapeut...
(Date:8/20/2008)...s have created a tiny motorized ,positioning devi... being ,developed for applications that include b...puter hard drives. , The device, called a monoli...anipulator" that precisely moves or senses movemen...tery environments for probing ,biological molecul...
(Date:8/20/2008)...etic code of a simple saltwater creature could hel... function in humans and other species. , A study...s down the genetic code of Trichoplax , a simple ... the world, even in the common household aquarium.... , genes that are also found in other animals - ou...
Breaking Biology News(10 mins):BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 2BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 3PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3New 'nano-positioners' may have atomic-scale precision 2New 'nano-positioners' may have atomic-scale precision 3Genome of saltwater creature could aid understanding of gene grouping 2As Billions in Blockbuster Drug Revenue Goes Off Patent Life Sciences Companies are Challenged to Fundamentally Change Future R 26D Strategies Accor 4345 1As Billions in Blockbuster Drug Revenue Goes Off Patent Life Sciences Companies are Challenged to Fundamentally Change Future R 26D Strategies Accor 4345 2As Billions in Blockbuster Drug Revenue Goes Off Patent Life Sciences Companies are Challenged to Fundamentally Change Future R 26D Strategies Accor 4345 3Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis 1676 1Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis 1676 2EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha 7 Nicotinic Agonist EVP 6124 in Patients with Schizophre 1674 1EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha 7 Nicotinic Agonist EVP 6124 in Patients with Schizophre 1674 2EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha 7 Nicotinic Agonist EVP 6124 in Patients with Schizophre 1674 3New Scan Sees Tumors Deep Inside Body 15749 1New Scan Sees Tumors Deep Inside Body 15749 2[0] BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses[0] PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet[1] New 'nano-positioners' may have atomic-scale precision[0] Genome of saltwater creature could aid understanding of gene grouping
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2[0] Cytiva's one45 Software Rebrands Healthcare Education Administration Products[0] Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events[0] New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation[0] Women's Alcohol Use Tied to Delayed Childbearing
| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |